Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Annals of Hematology|May 26, 2022
Oncology stewardship in acute myeloid leukemiaMadeleine A Ochs, Bernard L Marini, Anthony J Perissinotti, et al.
Leukemia Research|March 1, 2021
Hybrid chemotherapy regimen (FLAG-IDA-vincristine-prednisone) for acute leukemia with mixed-phenotype blastsJustin H Reid, Anthony J Perissinotti, Lydia L Benitez, et al.
Cancer Nursing|January 31, 2025
Identifying Adolescent and Young Adults' Preferences for Oncology Symptom Management Clinical Trial ParticipationRobert Knoerl, Liat Smener, Katherine Grandinetti, et al.
Journal of Adolescent and Young Adult Oncology|April 18, 2024
Exploring Adolescent and Young Adult Cancer Survivors' Experience with Cancer Treatment-Related Symptoms: A Qualitative Analysis of Semi-Structured InterviewsRobert Knoerl, Katherine Grandinetti, Liat Smener, et al.
Radiology. Imaging Cancer|November 14, 2025
Quantitative MRI Assessment of Bone Marrow Disease in Myelofibrosis: A Prospective StudyTanner H Robison, Annabel Levinson, Winston Lee, et al.
Infection Control and Hospital Epidemiology|October 18, 2021
Impact of number of lumens in central-venous catheters on central-line bloodstream infection (CLABSI) and venous thromboembolism (VTE) risk in patients with acute leukemiaAlina Varabyeva, Christabel Pui-See Lo, Adamo Brancaccio, et al.
Leukemia & Lymphoma|May 18, 2019
A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortageBernard L Marini, Julia Brown, Lydia Benitez, et al.
JAMA Network Open|December 5, 2022
Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19: A Phase 2 Randomized Clinical TrialJohn Cafardi, Carole Miller, Howard Terebelo, et al.
Leukemia & Lymphoma|March 29, 2022
Multicenter comparison of first salvage chemotherapy versus novel therapy regimens in adult relapsed/refractory acute lymphoblastic leukemiaMadeleine A Ochs, Bernard L Marini, Lydia L Benitez, et al.
Leukemia & Lymphoma|April 8, 2021
Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemiaLydia L Benitez, Anthony J Perissinotti, Caitlin R Rausch, et al.
Pageof 4